Veno-arterial extracorporeal membrane oxygenation with concomitant Impella versus concomitant intra-aortic-balloon-pump for cardiogenic shock
| العنوان: | Veno-arterial extracorporeal membrane oxygenation with concomitant Impella versus concomitant intra-aortic-balloon-pump for cardiogenic shock |
|---|---|
| المؤلفون: | Wing-Yiu George Ng, Kang Yin Michael Lee, Ka Man Fong, Chi Yuen Wong, Ka-Chun Alan Chan, Shek Yin Au, Chun-Fung Sunny Tsang |
| المصدر: | Perfusion. 38:51-57 |
| بيانات النشر: | SAGE Publications, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Advanced and Specialized Nursing, medicine.medical_specialty, business.industry, Cardiogenic shock, medicine.medical_treatment, General Medicine, 030204 cardiovascular system & hematology, medicine.disease, Peripheral, 03 medical and health sciences, surgical procedures, operative, 0302 clinical medicine, 030228 respiratory system, Internal medicine, Concomitant, medicine, Extracorporeal membrane oxygenation, Cardiology, Radiology, Nuclear Medicine and imaging, Balloon pump, Cardiology and Cardiovascular Medicine, business, Safety Research, Impella, Intra-aortic balloon pump |
| الوصف: | Introduction: The intra-aortic balloon pump (IABP) and Impella are left ventricular unloading devices with peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) in place and later serve as bridging therapy when VA-ECMO is terminated. We aimed to determine the potential differences in clinical outcomes and rate of complications between the two combinations of mechanical circulatory support. Methods: This was a retrospective, single institutional cohort study conducted in the intensive care unit (ICU) of Queen Elizabeth Hospital, Hong Kong. Inclusion criteria included all patients aged ⩾18 years, who had VA-ECMO support, and who had left ventricular unloading by either IABP or Impella between January 1, 2018 and October 31, 2020. Patients Results: Fifty-two patients with ECMO + IABP and 14 patients with ECMO + Impella were recruited. No statistically significant difference was observed in terms of ECMO duration (2.5 vs 4.6 days, p = 0.147), ICU LOS (7.7 vs 10.8 days, p = 0.367), and hospital LOS (14.8 vs 16.5 days, p = 0.556) between the two groups. No statistically significant difference was observed in the ECMO, ICU, and hospital mortalities between the two groups. Specific complications related to the ECMO and Impella combination were also noted. Conclusions: Impella was not shown to offer a statistically significant clinical benefit compared with IABP in conjunction with ECMO. Clinicians should be aware of the specific complications of using Impella. |
| تدمد: | 1477-111X 0267-6591 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d75d489e598212347c4d57d10af54ae5 https://doi.org/10.1177/02676591211033947 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....d75d489e598212347c4d57d10af54ae5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1477111X 02676591 |
|---|